NovoCure Limited

NVCR Healthcare Medical Devices

NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 63.9%, free cash flow grew 105.7% and total debt rose 100.7%, each against the same quarter a year earlier.

14.07 0.34 −2.36%
Market cap
$1.7B
P/E
0.0×
Fwd P/E
−10.8×
Dividend yield
—
F-score
4/9
Altman Z
0.43
Beneish M
−2.12
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
2.25 2.20 1.84 2.51
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
70.28 (80.06) (92.05) 216.13
P/B ratio
4.24 4.23 3.76 5.20
Price to Tangible BV
4.24 4.23 3.76 5.20
EV/Sales
0.94 1.80 1.54 2.15
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(17.53) (24.04) (38.59) (533.92)
EV/FCF
(9.27) (15.58) (21.58) (59.09)
Quick Ratio
1.50 2.71 2.70 2.70
Current Ratio
1.55 2.90 2.90 2.89
Net Debt/EBITDA
21.71 6.57 3.14 28.77
Debt/Assets
14.30% 24.25% 29.82% 24.63%
Debt/Equity
0.57 0.57 0.71 0.58
Asset Turnover
0.50 0.64 0.66 0.69
Operating CF/Net income
(0.55) 0.73 0.19 (0.52)
Capex/Depreciation
2.06 (10.37) (3.42) (4.03)
Interest Coverage
6.00 (72.00) (36.68) (5.59)
Research and Development Expense of Revenue
32.31% 34.93% 33.52% 28.02%
Selling, General and Administrative Expense of Revenue
62.48% 64.06% 82.85% 55.34%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
17.54% 11.37% 36.20% 9.27%
Graham Net Nets
0.12 0.13 0.14 0.10
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(12.46%) (9.44%) (14.04%) (8.58%)
Free Cash Flow Yield
(4.51%) (5.25%) (3.86%) (1.45%)
Revenue per Share
1.49 1.56 1.52 1.58
Operating CF per Share
0.18 (0.16) (0.12) 0.07
Capex per Share
(0.05) (0.04) (0.05) (0.06)
Free Cash Flow per Share
0.13 (0.21) (0.16) 0.01
Cash per Share
9.26 4.10 3.87 3.88
Shareholders Equity per Share
3.05 3.05 2.90 2.91
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
3.05 3.05 2.90 2.91
Free Cash Flow
14.92 (22.90) (18.67) 1.22
Working Capital
423.85 423.50 414.09 417.81
Capital Expenditures
(5.65) (4.90) (5.15) (6.92)
Net Current Asset Value
179.99 182.87 174.45 181.42
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.03 0.03 0.03 0.04
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
108.61 128.70 132.48 137.44
Average Payables
105.12 113.66 111.16 117.20
Average Inventory
39.10 38.10 41.46 41.22
Average Assets
1,291.59 1,022.56 1,018.37 1,020.53
Average Common Equity
351.06 350.32 346.34 343.77

Fold the line items

Columns are period end dates